Fundamental Data for HGSI

HUMAN GENO(NSDQ:HGSI)

Human Genome Sciences is a biopharmaceutical company with a pipeline of novel compounds in clinical development, including drugs to treat such diseases as hepatitis C, lupus, anthrax disease, cancer, rheumatoid arthritis and HIV/AIDS. Additional products are in clinical development by companies with which we are collaborating. Its mission is to discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody products.

# Employees: 880

Address: 14200 Shady Grove Road,Rockville,MD,USA

Phone: 301-309-8504

Fax: 301-309-8512

Website: www.hgsi.com

Email: Investor_Relations@hgsi.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Argeris N. Karabelas Ph.D. (Chmn.)

Thomas H. Watkins (Presi.; C.E.O.; Dir.)

Timothy C. Barabe (Sr. V.P.; C.F.O.; Princ. Acttg. Off.)

Richard J. Danzig (Dir.)

J??rgen Drews M.D. (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/25/2010

Mean EPS (Next Qtr): ($0.10)

Mean EPS (Year): ($0.01)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 6

Shares Performance

Period	HGSI	Compare to S&P
YTD	1,178.77 %	958.23 %
4 Weeks	45.05 %	37.70 %
12 Weeks	40.39 %	30.74 %

Shares Information

Analyst Coverage: Y

Avg Volume: 8109341

Shares Outstanding: 162M

Market Cap: $4.41B

52 Week High: $28.97

52 Week Low: $0.48

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 10/6/2000 HGSI split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: 33.33 %

EPS Growth in Last Year: 30.43 %

Sales Growth in Last Quarter: -29.41 %

Sales Growth in Last Quarter: 61.33 %

Financials

Qtr Book Value: $15.67

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 18.720